THE WIRE · № 82333
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors
01 THE MACHINE READ
WHY IT MATTERS.
Forecast market-growth reports are promotional pipeline summaries; they signal R&D interest in NEPC therapies but no tradable catalyst.
Niche oncology forecast, no near-term market impact
Clinical data for DLL3 or ADC candidates
Forecast reports often overstate eventual market size
FULL DISPATCH
The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of prostate cancer. Additionally, the ongoing clinical development of investigational therapies such as Peluntamig (PT217; Phanes...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Odacova Health Unveils Nine-Year Canine Longevity Study at ALOS 2026, Charting a New Path to Extend Pet Healthspan2026-10-15 12:32 UTC
Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma2026-10-15 13:05 UTC
Heart implant maker BioVentrix withdraws plans for Nasdaq IPO2026-10-15 13:56 UTC
Lilly confirms date and conference call for third-quarter 2026 financial results announcement2026-10-15 14:00 UTC
Iambic banks $150M from IPO to advance cancer pipeline2026-10-15 14:04 UTC
TANEA "REBEL" BROOKS STEPS UP HER LEADERSHIP ROLE, JOINING I AM ALS AS HONORARY BOARD MEMBER FOLLOWING SENATE PASSAGE OF ACT FOR ALS2026-10-15 14:21 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.